How Embryo Biopsy Works for PGT: What the Lab Does Before Your Embryos Are Frozen

The nurse’s phone call is short: eleven eggs retrieved, eight fertilized, and the lab will “watch them through the week.” What she does not describe, because almost nobody does, is the quiet, high-magnification work that happens next: an embryologist steadying a five-day-old embryo on a glass pipette, loosening a few cells from its outer shell, and slipping them into a labeled tube smaller than a grain of rice.

If you have been told your embryos will be biopsied and frozen before anyone talks about a transfer, you probably want to know exactly what that means. Understanding how embryo biopsy works for PGT takes away a good deal of the mystery, and it also sets realistic expectations about what the test can and cannot tell you.

This explainer follows the embryo from the culture dish to the freezer, describes what the genetics lab does with those cells, and looks honestly at what the evidence says about whether any of it improves your chances.

How embryo biopsy works for PGT: what actually happens in the lab

Preimplantation genetic testing, or PGT, is the umbrella term for analyzing an embryo’s DNA before it is placed in the uterus. The biopsy is the physical act that makes that analysis possible.

By day 5 to 7 after fertilization, a healthy embryo has become a blastocyst: a hollow ball of roughly a hundred cells with a fluid-filled cavity, a compact inner cluster that will become the baby, and a thin outer layer called the trophectoderm that will become the placenta. The embryo is still wrapped in its zona pellucida, a protein shell it will normally shed on its own before implanting.

The embryologist works at a microscope fitted with two fine glass tools. One holds the embryo gently by suction. The other, a hollow pipette, draws a few trophectoderm cells outward through a small opening in the shell, often made with a brief laser pulse. The cells are separated from the embryo either with the laser or by a gentle flicking motion against the holding pipette. The whole maneuver typically takes a few minutes per embryo.

Those cells are washed, placed in a tube containing a buffer solution, sealed and labeled with the embryo’s unique identifier. Within a short time, usually the same hour, the embryo itself is frozen by vitrification, a rapid freezing method described later in this article.

Two details matter most. First, nothing is taken from the inner cell mass, the part that becomes the fetus. Second, the biopsy is a sample, not a census: the lab reads a handful of placental cells and infers the genetics of the whole embryo from them. Almost every strength and limitation of PGT flows from that inference, as MedlinePlus explains in its overview of preimplantation testing.

Is embryo biopsy the same as PGT?

No, and the distinction is worth holding onto because the two words are often used interchangeably in waiting rooms and online forums.

The biopsy is a procedure. It happens in the embryology lab, performed by an embryologist, and it produces a tube of cells. PGT is a test. It happens in a genetics laboratory, often in a different building, performed by molecular biologists who never see the embryo. One supplies the raw material; the other interprets it.

Think of it the way you might think of a blood draw and a cholesterol panel. The needle in your arm is not the result on the page, even though you cannot get one without the other.

Several practical consequences follow:

• An embryo can be biopsied and frozen without ever being tested, for instance if the family later decides against analysis. The cells can be stored or discarded according to the consent you signed.
• The same biopsy sample can, in some laboratories, be used for more than one type of PGT, such as screening for chromosome number and for a specific inherited condition at once.
• A biopsy can technically succeed while the test returns “no result,” because the sample contained too little usable DNA. That is a testing outcome, not a sign that the embryo itself is abnormal.

When you read your paperwork, you will usually find two separate consent forms: one for the biopsy and freezing, held by the fertility lab, and one for the genetic analysis, held by the testing laboratory. Reading both tells you exactly who is responsible for which step, and whom to call with questions about each. MedlinePlus describes PGT as one of several categories of genetic testing, distinct from the clinical procedure used to collect the sample.

Trophectoderm biopsy day 5 to 7: why then, and which cells are taken

Early PGT, in the 1990s and 2000s, removed one or two cells from a day 3 embryo that had only six to eight cells in total. Taking a quarter of an embryo’s cells is a heavy price, and results from a single cell were often unreliable. Most laboratories moved to the blastocyst stage as culture systems improved, and the NHS notes that embryos are now routinely kept in the lab for up to 6 days before transfer or freezing.

Three advantages come with waiting:

• The embryo has many more cells, so removing a small cluster represents a far smaller fraction of the whole.
• The trophectoderm and inner cell mass have separated, so the embryologist can deliberately avoid the cells that become the fetus.
• Embryos that were never going to develop have usually stopped by day 5, so fewer biopsies are performed on embryos with no future.

Embryologists aim for a small cluster of trophectoderm cells: enough DNA for the genetics lab to work with, few enough to leave the embryo’s structure intact. Laboratories set their own targets, and your embryologist can tell you what theirs is.

The location matters, too. Cells are taken from the side of the blastocyst opposite the inner cell mass whenever the embryo’s orientation allows it. If an embryo has not yet expanded enough by day 5, the lab will often give it another day or two rather than force an early biopsy. This is why you may hear that some embryos were frozen on day 5, others on day 6 or day 7.

One honest caveat: the placenta and the fetus develop from different cell lines, and they occasionally disagree genetically. That reality underpins the discussion of mosaic results later in this article.

What happens to the cells after they leave the embryo

Once the trophectoderm cells are sealed in their tube, they begin a journey the patient never sees. The tube is chilled or frozen, packed with the embryo’s identification code and shipped to the genetics laboratory, sometimes across the hall, often across the country.

The first problem the genetics lab faces is scarcity. A handful of cells carries only a minute quantity of DNA, far too little to read directly. So the lab performs whole genome amplification, a chemical copying process that makes millions of copies of the DNA in the sample. Amplification is powerful, but it can introduce errors and uneven coverage, which is one reason results carry a small margin of uncertainty.

Next comes the actual reading. Most laboratories today use next-generation sequencing, a technology that breaks DNA into fragments, reads each one, and uses software to count how many fragments map to each chromosome. If chromosome 21 contributes roughly half again as many reads as expected, the software flags a likely extra copy, the pattern seen in Down syndrome.

For PGT-M, the search for a specific inherited condition, the lab takes a different approach. It looks at the exact gene variant carried in the family, usually alongside nearby genetic markers inherited together with it, a technique that adds a second line of evidence in case amplification misses the variant itself.

Every result is then reviewed by a geneticist and reported against the embryo’s identifier. Chain-of-custody checks, in which two staff members independently verify labels at each handoff, are standard practice, because a mislabeled tube would be far worse than no result at all.

Your fertility team receives the report and translates it into recommendations. The testing laboratory typically does not contact patients directly, so questions about the report go to your clinic or a genetic counselor.

Why embryos are frozen right after biopsy: vitrification explained

A day 5 embryo has, at most, a day or two left before it must implant or stop developing. Genetic results take longer than that. So the biopsied embryo is frozen while its cells travel, and the transfer, if one happens, moves to a later cycle.

Vitrification is the freezing method used almost universally now. The word means turning to glass. The embryo is bathed in a series of protective solutions that draw water out of its cells and replace it with cryoprotectants, then plunged into liquid nitrogen so fast that ice crystals never have time to form. Ice is the enemy: crystals shred cell membranes. Glass-like solidification avoids that damage.

The Mayo Clinic notes that frozen embryos are commonly used in IVF, and that freezing allows transfer to be timed to a cycle when the uterine lining is receptive. For PGT patients this becomes the default sequence: retrieval, fertilization, culture, biopsy, freeze, wait for results, then a separate frozen embryo transfer cycle.

Some patients worry that freezing adds risk on top of biopsy. Modern vitrification has high survival on thawing, and your laboratory can share its own survival figures, which vary by lab. Two things are worth knowing:

• An embryo that was biopsied has a small opening in its shell. Laboratories have adapted freezing protocols for this, and it is a routine consideration rather than a complication.
• The embryo is stored under your name and code, with legal storage limits that differ by country. The NHS sets out its own rules in its IVF guidance; your consent forms will state what applies to you.

The frozen wait can feel like the hardest part of the process. It is also the part that gives the genetics lab time to do careful work, and gives your body time to recover from stimulation before a transfer.

PGT-A vs PGT-M vs PGT-SR: what each test looks for

The same biopsy can feed three different kinds of analysis, and people frequently conflate them. Each answers a different question, and each suits a different family.

Test	What it looks for	Who it is usually discussed with	What it cannot tell you
PGT-A (aneuploidy)	Whether the embryo has the expected number of chromosomes, 46 in total	People wanting to prioritize embryos for transfer, often discussed more with advancing age or recurrent loss	Anything about single-gene conditions; overall health, intelligence or traits
PGT-M (monogenic)	A specific inherited condition already known in the family, such as cystic fibrosis or Huntington disease	Couples who both carry, or one of whom carries, a known disease-causing variant	Chromosome count, unless PGT-A is added; conditions not tested for
PGT-SR (structural rearrangement)	Unbalanced pieces of chromosomes in embryos from a parent with a balanced translocation or inversion	People whose own karyotype shows a rearrangement, often found after miscarriages	Whether the embryo carries the balanced form, in many labs

Aneuploidy means an abnormal number of chromosomes. Monogenic means caused by a single gene. A structural rearrangement is a chromosome with a piece moved, flipped or swapped, which may cause no problems for the carrier but can produce unbalanced embryos.

PGT-M requires preparation before your IVF cycle even starts. The genetics lab usually needs DNA samples from both partners and often from other relatives to build a family-specific test, which can take weeks. MedlinePlus lists preimplantation testing among the uses of genetic testing and notes it is used to detect genetic changes in embryos created through assisted reproduction.

Choosing among these is not a matter of picking the most thorough. It is a matter of matching the test to the question your family is actually asking, which is a conversation for a genetic counselor.

Who is usually offered PGT, and who is usually asked to wait

PGT-M and PGT-SR have clear medical logic. If a family carries a serious single-gene condition or a parent has a chromosome rearrangement, testing embryos offers an alternative to prenatal testing after a pregnancy is established. Guidelines in most countries support these uses, and the NHS describes preimplantation genetic testing as an option for people at risk of passing on a specific inherited condition.

PGT-A is more contested. It is often discussed with people who are older, who have had repeated miscarriages, who have had several unsuccessful transfers, or who wish to transfer one embryo at a time and want help choosing. Yet the evidence, reviewed in the next sections, does not show a clear benefit for everyone, and professional bodies differ on how strongly to recommend it.

Who is usually asked to wait, or counseled against testing?

• People expected to have very few blastocysts. If only one or two embryos reach day 5, biopsying them adds procedure and delay without leaving much to choose between.
• People whose embryos are not yet at a stage suitable for biopsy. Labs prefer to give a slow embryo another day rather than sample it early.
• People who have not yet met a genetic counselor to discuss what results would mean for their decisions, including what they would do with a mosaic or unclear result.
• People in the middle of a fresh transfer plan, since PGT almost always means switching to a frozen cycle.

Age is often raised as the main reason for PGT-A because the proportion of chromosomally abnormal eggs rises with age, a pattern the Mayo Clinic notes in its discussion of age and IVF outcomes. Whether testing changes the eventual outcome for a given person is a different question from whether abnormal embryos exist. Your treating team weighs both.

Embryo biopsy for PGT timeline: what the next days and weeks look like

Most people have a rough picture of IVF up to egg retrieval. What follows is less familiar, so here is the typical sequence, with the caveat that your clinic’s schedule is the one that counts.

• Day 0. Eggs are retrieved and fertilized, usually by ICSI when PGT is planned. ICSI, intracytoplasmic sperm injection, places a single sperm inside each egg and avoids stray sperm cells contaminating the later biopsy sample.
• Days 1 to 4. Embryos grow in incubators. You will usually get a fertilization update on day 1 and sometimes a progress call on day 3.
• Days 5 to 7. Embryos that reach the expanded blastocyst stage are biopsied and vitrified, sometimes on different days. The NHS notes embryos are cultured for up to 6 days, with some labs extending to day 7.
• The following weeks. Samples travel to the genetics lab. Turnaround varies by laboratory and test type; PGT-M often takes longer than PGT-A. Your clinic will tell you its usual range.
• Results consultation. A clinician or genetic counselor reviews the report with you and discusses which embryos are candidates for transfer.
• Frozen embryo transfer cycle. This begins with your next suitable menstrual cycle or later, depending on recovery and scheduling. The lining is prepared, either naturally or with hormonal medication chosen by your prescribing clinician, and the selected embryo is thawed on the day of transfer.

Physically, the days after retrieval are about recovery from stimulation and the procedure itself: bloating, mild cramping and fatigue are common and usually ease over a week or so, according to the Mayo Clinic. The embryos’ journey happens without you, which some people find restful and others find maddening.

Emotionally, the gap between biopsy and results is a distinctive stretch of waiting. Many clinics offer counseling during it, and it is reasonable to ask for a clear date when you can expect the report.

How to read a PGT report: euploid, aneuploid, mosaic and no result

A PGT-A report lists each embryo by number, its day of biopsy, its morphology grade, and a genetic classification. Four categories cover almost everything.

Euploid means the sample showed the expected chromosome count with no detected gains or losses. It is the result people hope for, and it is a statement about the biopsied cells, not a guarantee about the fetus.

Aneuploid means the sample showed a whole extra or missing chromosome, or a large segment gained or lost, in essentially all cells analyzed. Most such embryos will not implant or will miscarry, which is the logic of the test. Reports name the chromosome involved, and a genetic counselor can explain whether a given finding is compatible with a live birth, as trisomy 21 can be.

Mosaic means the sample showed a mixture: some cells with the normal count, some without. Because the sample is only a few placental cells, a mosaic reading may reflect the whole embryo, only the placenta, or an artifact of amplification. Laboratories set thresholds for what they call mosaic, and those thresholds differ. Healthy babies have been born from embryos reported as mosaic, and professional groups increasingly treat them as lower-priority candidates rather than as unusable. Whether and how to transfer one is a decision for you and your team with counseling.

No result, sometimes written as no call or no amplification, means the DNA was insufficient or of poor quality. It says nothing about the embryo’s health. Options include rebiopsy after thawing, transfer without a result, or leaving the embryo frozen.

PGT-M and PGT-SR reports use different language: affected, unaffected, carrier, or balanced and unbalanced. Ask for the report in writing and for time with someone who can walk through it line by line. MedlinePlus offers plain-language guidance on what genetic test results mean and their limitations.

Do PGT-A tested embryos have a higher success rate or lower miscarriage risk?

This is the question behind every other question, and the honest answer is more nuanced than most marketing suggests.

The intuition is straightforward. Most miscarriages involve chromosome abnormalities. If you can screen those embryos out, each transfer should have a better chance and the path to a baby should be shorter. Per transfer, that is broadly what studies show: a euploid embryo is more likely to implant than an untested one. But per cycle, once you count every embryo a person had, the picture changes, because biopsy and testing cannot create more good embryos. They can only sort the ones you have, and sorting has its own error rate.

The largest randomized trial to date, published in Fertility and Sterility and indexed on PubMed, compared PGT-A with standard selection in women with good prospects. Overall ongoing pregnancy rates per intended transfer were similar in both groups, about half of participants in each. A benefit appeared only in the subgroup aged 35 to 40, and only when measured per embryo transfer rather than per person.

A Cochrane systematic review from 2020, also on PubMed, pooled the randomized evidence and concluded there was insufficient good-quality evidence of a difference in cumulative live birth or in miscarriage rate between IVF with and without PGT-A. The authors called for more well-designed trials before routine use.

So are tested embryos less likely to miscarry? Each transferred euploid embryo probably carries a lower miscarriage risk than an untested embryo, but across a whole treatment course the trials have not proven fewer losses overall, partly because some euploid embryos still miscarry and some abnormal-appearing embryos might have been healthy.

None of this means PGT-A is useless. It may reduce the number of transfers before success, spare some people the experience of a miscarriage from an aneuploid embryo, and support single-embryo transfer. Those are real, if modest, goals. Your care team can explain how the evidence applies to your age and embryo numbers.

Does embryo grading still matter with PGT?

Yes, and knowing why helps make sense of a report where the “best-looking” embryo is not the one your team recommends first.

Embryo grading is the embryologist’s visual assessment under the microscope. For blastocysts it typically records how expanded the embryo is, how compact and well-defined the inner cell mass looks, and how many cohesive cells the trophectoderm has. Grades are shorthand for developmental competence, and before PGT they were the main tool for choosing which embryo to transfer.

PGT-A adds a second, independent dimension. A beautifully graded embryo can be aneuploid, and a modestly graded one can be euploid. Genetics and appearance are correlated but far from identical, which is precisely why grading alone was never a reliable chromosome screen.

Once genetic results are in, grading still does two useful jobs:

• Among several euploid embryos, morphology helps rank them. Better-graded euploid embryos tend to implant more often than poorly graded euploid embryos, so teams usually transfer the higher grade first.
• The day of biopsy carries information, too. Embryos that reached the biopsy stage on day 5 tend to fare somewhat better than those that needed until day 6 or 7, though euploid day 6 embryos remain good candidates.

What grading cannot do is override a genetic result. A top-grade embryo reported as aneuploid for a chromosome incompatible with life will not be recommended for transfer regardless of how it looks. Conversely, a euploid embryo with a lower grade should not be dismissed; many such embryos become healthy pregnancies.

The Mayo Clinic notes that embryo selection in IVF relies on assessing development and, where used, genetic testing. Think of the two as complementary filters rather than competitors: genetics narrows the field, morphology orders what remains. Your embryologist can explain your lab’s grading scheme, since letters and numbers differ between laboratories.

Embryo biopsy risks: is the procedure safe for the embryo?

Removing cells from an embryo sounds alarming, and it is fair to ask whether the procedure causes harm. The evidence is reassuring in some respects and incomplete in others.

The most direct concern is that biopsy damages the embryo so that it fails to survive freezing, thawing or implantation. Trophectoderm biopsy at the blastocyst stage appears to be well tolerated in experienced hands, in contrast to older day 3 biopsy, which removed a larger fraction of the embryo and was associated with reduced implantation. The Cochrane review discussed earlier found no clear evidence that PGT-A lowered live birth compared with untested embryos, which argues against a large harmful effect, though it does not rule out a small one.

Other risks are less about the embryo and more about the information:

• False results. A euploid call does not guarantee a chromosomally normal fetus, and an aneuploid call could in rare cases lead to discarding an embryo that would have been healthy. Prenatal testing is still offered after a PGT pregnancy for this reason.
• No result. Some embryos yield no usable DNA and may require a second thaw and biopsy.
• Fewer embryos for transfer. If mosaic or uncertain embryos are set aside, some people end up with fewer options than they would have had without testing.
• Delay. PGT shifts transfer to a later frozen cycle, which matters more to some people than others.

Long-term child health after trophectoderm biopsy has been studied in follow-up cohorts without a consistent signal of harm, but these children are still young and the studies are observational. Honest counseling states that plainly.

Skill matters. Biopsy technique varies between embryologists, and laboratories track their own outcomes. Asking how many biopsies your lab performs and how it monitors survival after thaw is a legitimate question, and a good lab will welcome it.

What people often get wrong about embryo biopsy and PGT

Some of the most persistent misunderstandings arrive by word of mouth from people who mean well. Here are the ones that cause the most confusion.

“The biopsy takes cells from the baby.” It does not. Cells come from the trophectoderm, which forms the placenta. The inner cell mass, which becomes the fetus, is deliberately avoided.

“A euploid result means a healthy baby.” PGT-A screens chromosome number in a small sample of placental cells. It does not detect most birth defects, single-gene conditions not specifically tested for, or anything about development after birth. The Cochrane review found no proven improvement in overall live birth, and a euploid embryo can still miscarry.

“PGT makes more good embryos.” Testing sorts; it cannot add. If a cycle produces three blastocysts, testing will tell you something about those three and nothing more.

“Mosaic embryos are abnormal and should be discarded.” Mosaic results reflect a mixture of cells in the sample and may not represent the fetus. Healthy births have followed mosaic transfers, and professional guidance increasingly frames them as lower-priority rather than unusable. Decisions belong with you and a genetic counselor.

“PGT lets you choose eye color or intelligence.” Clinical PGT does not test for traits, and in many countries doing so is prohibited. Sex may be reported because sex chromosomes are counted, and rules about acting on that information vary by jurisdiction.

“Once embryos are tested, prenatal testing is unnecessary.” Because PGT has an error rate and samples only placental cells, standard prenatal screening or diagnostic testing is still offered in pregnancy, as MedlinePlus notes in describing the limits of preimplantation testing.

“Everyone doing IVF should test.” The evidence does not support universal PGT-A, and for people with few embryos it may add delay without benefit. This is a personalized decision, not a default.

Questions to ask your care team before embryo biopsy

The consent conversation is your chance to turn a general process into your specific plan. These questions tend to surface the details that matter most, and none of them should feel awkward to ask.

• Which type of PGT are you recommending for me, and what specific question is it meant to answer?
• Given my age and expected number of blastocysts, what does the evidence suggest testing would change for me?
• How many trophectoderm cells does the lab aim to take, and who performs the biopsies?
• What proportion of your lab’s biopsied embryos survive thawing, and how do you track that?
• How long does the genetics laboratory usually take to return results for this test?
• How does the lab define and report mosaic embryos, and what is your clinic’s policy on transferring them?
• What happens if a sample returns no result? Would you rebiopsy, transfer untested or leave the embryo frozen?
• Will I meet a genetic counselor before and after results, and how do I reach them with questions?
• If PGT-M is planned, what samples do you need from family members, and how long will building the test take?
• What are my options for embryos that are aneuploid, mosaic, or that I decide not to use, and what do the consent forms say about storage and disposal?
• Will you still recommend prenatal screening or diagnostic testing if I become pregnant with a tested embryo?
• How does PGT change my timeline to a frozen embryo transfer, and what recovery is expected between retrieval and that cycle?

Write the answers down, or ask whether you can record the conversation. The NHS and Mayo Clinic both encourage patients undergoing IVF to ask about laboratory practices and to seek counseling, and clinics accustomed to PGT will have clear, specific answers. Vague ones are a signal to ask again.

Finally, ask what you would do with each possible result before you have any. People who have rehearsed the mosaic conversation in advance usually find the real one far less destabilizing.

When to call your doctor

Embryo biopsy itself happens to the embryo, not to you, so it carries no direct physical symptoms. The days around it, however, coincide with recovery from ovarian stimulation and egg retrieval, and that is when problems can appear.

Call your fertility clinic promptly, or seek urgent care if the clinic is closed, for any of the following after egg retrieval:

• Severe or rapidly worsening abdominal pain, or pain that is not relieved by the measures your team advised.
• Abdominal swelling that increases quickly, or a sudden gain in weight over a day or two, both possible signs of ovarian hyperstimulation syndrome, a complication in which fluid shifts into the abdomen.
• Shortness of breath, chest pain, or breathing that feels harder when lying flat.
• Passing much less urine than usual, or dark urine despite drinking.
• Persistent vomiting or inability to keep fluids down.
• Fever, chills, or heavy vaginal bleeding beyond light spotting.
• A swollen, painful or red calf or thigh, which can indicate a blood clot.

The Mayo Clinic and NHS both describe ovarian hyperstimulation syndrome as an uncommon but potentially serious complication of IVF stimulation, and both advise contacting the care team early rather than waiting to see whether symptoms settle.

Emotional distress also merits a call. The wait for genetic results, and the results themselves, can trigger anxiety or low mood that interferes with sleep, work or relationships. Fertility clinics can connect you with counselors familiar with this exact situation.

If your results conversation leaves you uncertain about what a classification means or what your options are, ask for a follow-up appointment with a genetic counselor before making any decision. Every choice about which embryo to transfer, whether to rebiopsy, or whether to proceed at all rests with you and your treating team, informed by the evidence and by your own priorities.

Frequently asked questions

Is embryo biopsy the same as PGT?

No. Embryo biopsy is the laboratory procedure in which an embryologist removes a few outer cells from a day 5 to 7 embryo. PGT, preimplantation genetic testing, is the analysis of those cells in a genetics laboratory. One collects the sample and the other interprets it. An embryo can be biopsied and frozen without being tested, and a biopsy can succeed while the test returns no result.

What is the PGT-A success rate for a tested embryo?

Per transfer, a euploid embryo is more likely to implant than an untested one, but success across a whole treatment course is less clear. In the largest randomized trial, about half of participants had an ongoing pregnancy whether or not PGT-A was used, and a 2020 Cochrane review found insufficient evidence of improved cumulative live birth. Your own outlook depends on age and embryo numbers, which your team can discuss.

Does embryo grading matter with PGT?

Yes. Grading is the embryologist’s visual assessment of expansion, inner cell mass and trophectoderm quality, and it remains useful for ranking embryos that all test euploid. It cannot override a genetic result, though: a top-grade aneuploid embryo is not recommended for transfer, and a lower-grade euploid embryo remains a genuine candidate. Genetics narrows the field; morphology orders what remains.

Are PGT tested embryos less likely to miscarry?

Each transferred euploid embryo probably carries a lower miscarriage risk than an untested one, because most miscarriages involve chromosome abnormalities. Across a whole treatment course, however, randomized trials pooled in the 2020 Cochrane review did not show a proven difference in miscarriage rate with PGT-A. Euploid embryos can still miscarry, since the test samples only placental cells and has an error rate.

What does a PGT-A mosaic embryo result mean?

A mosaic result means the biopsied cells showed a mixture of normal and abnormal chromosome counts. Because only a few placental cells are sampled, this may reflect the whole embryo, only the placenta, or a testing artifact. Healthy babies have been born from embryos reported as mosaic, and professional guidance increasingly treats them as lower-priority rather than unusable. Decisions about transfer belong with you and a genetic counselor.

What is PGT-M and how is it different from PGT-A?

PGT-M tests embryos for a specific single-gene condition already known in a family, such as cystic fibrosis, while PGT-A counts chromosomes to screen for aneuploidy. PGT-M requires building a family-specific test before the IVF cycle, usually with DNA from both partners and sometimes relatives. The same biopsy sample can sometimes be used for both tests if the laboratory offers combined analysis.

What are the risks of embryo biopsy to the embryo?

Trophectoderm biopsy at the blastocyst stage appears well tolerated in experienced laboratories, and the 2020 Cochrane review found no clear evidence that PGT-A lowers live birth compared with untested embryos. Risks are mostly informational: false results, no-result samples that may need rebiopsy, fewer embryos judged suitable for transfer, and delay to a frozen cycle. Long-term child follow-up has not shown consistent harm but remains limited.

Why are embryos frozen after biopsy instead of transferred fresh?

Genetic results take longer than a day 5 embryo can wait in the dish, so embryos are vitrified, a rapid glass-like freezing that avoids ice crystal damage, while the cells are analyzed. Transfer then happens in a later frozen embryo transfer cycle, which also allows the uterine lining to be prepared at the right time and gives the body a chance to recover from stimulation.

How long does it take to get PGT results after embryo biopsy?

Turnaround depends on the genetics laboratory and the type of test. PGT-A generally returns faster than PGT-M, which involves a custom family test. Clinics typically quote a range in weeks rather than days, and the embryos remain safely frozen throughout. Ask your clinic for its usual timeline and a specific date by which you can expect to review the report with a clinician or genetic counselor.

Can PGT tell the sex of the embryo or screen for traits?

PGT-A counts all chromosomes, including the sex chromosomes, so sex is usually known to the laboratory and may appear on the report depending on local rules. Clinical PGT does not test for traits such as eye color or intelligence, and selecting embryos for non-medical reasons is prohibited in many countries. Ask your clinic how it reports sex and what its policy allows.

References

• MedlinePlus Genetics: What are the uses of genetic testing?
• NHS: IVF, what happens

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.